2-二甲基氨基嘧啶-5-硼酸 | 756817-82-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-二甲基氨基嘧啶-5-硼酸
• 中文别名: (2-(二甲基氨基)嘧啶-5-基)硼酸；2 -二甲基氨基嘧啶- 5 -硼酸
• 英文名称: (2-(dimethylamino)pyrimidin-5-yl)boronic acid
• 英文别名: [2-(dimethylamino)pyrimidin-5-yl]boronic acid
• CAS: 756817-82-0
• 化学式: C₆H₁₀BN₃O₂
• mdl: MFCD10696933
• 分子量: 166.975
• InChiKey: JHGMROYFIMQNCI-UHFFFAOYSA-N

物化性质

• 沸点：
  375.0±52.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.45
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  69.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R43
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Dimethylaminopyrimidine-5-boronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Dimethylaminopyrimidine-5-boronic acid
CAS number: 756817-82-0

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H10BN3O2
Molecular weight: 167.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-氯-5-氟苄醇可作为医药合成的中间体使用。

反应信息

• 作为反应物：
  描述：

  2-二甲基氨基嘧啶-5-硼酸 在 bis(1,5-cyclooctadiene)nickel (0) 、 potassium tert-butylate 、 N,N'-dimesityl-4,5-dihydro-1H-imidazolium tetrafluoroborate 作用下， 以 四氢呋喃 、 甲苯 、 正丁醇 为溶剂， 反应 24.0h， 生成 N,N-dimethyl-5-[(R)-naphthalen-2-yl(phenyl)methyl]pyrimidin-2-amine
  参考文献：
  名称：

  苯甲基氨基甲酸酯与芳基硼酸酯的立体特异性镍催化交叉偶联中的保留或反转：用非手性催化剂控制绝对立体化学

  摘要：

  已经开发了苄基氨基甲酸酯和新戊酸酯与芳基和杂芳基硼酸酯的立体有择偶联。根据配体的性质，反应以选择性反转或保留在亲电碳上进行。三环己基膦配体为产物提供保留，而 N-杂环卡宾配体为产物提供反转。

  DOI：

  10.1021/ja311783k

文献信息

• [EN] NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE<br/>[FR] DÉRIVÉS DE NAPHTHYRIDINE EN TANT QU'INHIBITEURS D'UN FACTEUR INDUCTIBLE PAR L'HYPOXIE
  申请人：FIBROGEN INC

  公开号：WO2012106472A1

  公开（公告）日：2012-08-09

  The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).

  本公开涉及能够抑制HIF羟化酶活性的新化合物、方法和组合物，从而增加缺氧诱导因子（HIF）的稳定性和/或活性。
• Efficient Synthesis of 1,9-Substituted Benzo[<i>h</i>][1,6]naphthyridin-2(1<i>H</i>)-ones and Evaluation of their <i>Plasmodium falciparum</i> Gametocytocidal Activities
  作者：Hao Li、Wei Sun、Xiuli Huang、Xiao Lu、Paresma R. Patel、Myunghoon Kim、Meghan J. Orr、Richard M. Fisher、Takeshi Q Tanaka、John C. McKew、Anton Simeonov、Philip E. Sanderson、Wei Zheng、Kim C. Williamson、Wenwei Huang

  DOI：10.1021/acscombsci.7b00119

  日期：2017.12.11

  A novel three-component, two-step, one-pot nucleophilic aromatic substitution (SNAr)–intramolecular cyclization–Suzuki coupling reaction was developed for the synthesis of benzo[h][1,6]naphthyridin-2(1H)-ones (Torins). On the basis of the new efficiently convergent synthetic route, a library of Torin analogs was synthesized. The antimalarial activities of these compounds were evaluated against asexual

  为合成苯并[ h ] [1,6]萘啶-2（1 H），开发了一种新颖的三组分，两步，一锅亲核芳香取代（S N Ar）-分子内环化-Suzuki偶联反应。-一个（Torins）。在新的有效收敛的合成路线的基础上，合成了都灵类似物的文库。使用生长抑制测定法评估这些化合物对无性寄生虫的抗疟活性，并使用生存力测定法评估配子细胞。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：Geneste Hervé

  公开号：US20130005705A1

  公开（公告）日：2013-01-03

  The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及新型的氨基甲酸酰胺化合物、含有它们的药物组合物及其在治疗中的应用。这些化合物具有宝贵的治疗特性，特别适用于治疗或控制神经疾病和精神疾病，用于改善与这些疾病相关的症状，并用于降低这些疾病的风险。
• [EN] IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRIMIDINE EN TANT QU'AGENTS ANTIBACTERIENS
  申请人：WARNER LAMBERT CO

  公开号：WO2005089763A1

  公开（公告）日：2005-09-29

  Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

  公开了式I的化合物及其制备方法。进一步公开了制备式I生物活性化合物的方法，以及包含式I化合物的药用可接受组合物的方法。本文公开的式I化合物可用于各种应用，包括用作抗菌剂。
• [EN] BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF<br/>[FR] COMPOSÉS BENZOPYRAZOLE ET ANALOGUES DE CEUX-CI
  申请人：BIOCRYST PHARM INC

  公开号：WO2017136395A1

  公开（公告）日：2017-08-10

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising a compound of formula (I), and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by aberrant complement system activity.

  揭示了式（I）的化合物及其药学上可接受的盐。这些化合物是裂解系统的抑制剂。还提供了包含式（I）化合物的药物组合物，以及涉及使用这些化合物和组合物在治疗和预防由异常裂解系统活性特征的疾病和状况中的方法。